Emily Mason-Osann
Predoctoral Trainee
Boston University Chobanian & Avedisian School of Medicine, Graduate Medical Sciences

I am a graduate student studying the Alternative Lengthening of Telomeres (ALT) pathway

01/01/2019 - 12/31/2020 (PI)
PhRMA Foundation


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Mason-Osann E, Pomeroy AE, Palmer AC, Mettetal JT. Synergistic Drug Combinations Promote the Development of Resistance in Acute Myeloid Leukemia. Blood Cancer Discov. 2024 Mar 01; 5(2):95-105. PMID: 38232314; PMCID: PMC10905516; DOI: 10.1158/2643-3230.BCD-23-0067;
  2. Mason-Osann E, Terranova K, Lupo N, Lock YJ, Carson LM, Flynn RL. RAD54 promotes alternative lengthening of telomeres by mediating branch migration. EMBO Rep. 2020 06 04; 21(6):e49495.View Related Profiles. PMID: 32337843; PMCID: PMC7271314; DOI: 10.15252/embr.201949495;
  3. Panier S, Maric M, Hewitt G, Mason-Osann E, Gali H, Dai A, Labadorf A, Guervilly JH, Ruis P, Segura-Bayona S, Belan O, Marzec P, Gaillard PHL, Flynn RL, Boulton SJ. SLX4IP Antagonizes Promiscuous BLM Activity during ALT Maintenance. Mol Cell. 2019 10 03; 76(1):27-43.e11.View Related Profiles. PMID: 31447390; PMCID: PMC6863466; DOI: 10.1016/j.molcel.2019.07.010;
  4. Mason-Osann E, Gali H, Flynn RL. Resolving Roadblocks to Telomere Replication. Methods Mol Biol. 2019; 1999:31-57.View Related Profiles. PMID: 31127568
  5. Gali H, Mason-Osann E, Flynn RL. Direct Visualization of DNA Replication at Telomeres Using DNA Fiber Combing Combined with Telomere FISH. Methods Mol Biol. 2019; 1999:319-325.View Related Profiles. PMID: 31127588
  6. Mason-Osann E, Dai A, Floro J, Lock YJ, Reiss M, Gali H, Matschulat A, Labadorf A, Flynn RL. Identification of a novel gene fusion in ALT positive osteosarcoma. Oncotarget. 2018 Aug 28; 9(67):32868-32880.View Related Profiles. PMID: 30214690; PMCID: PMC6132345; DOI: 10.18632/oncotarget.26029;
  7. Mason-Osann E, Hollevoet K, Niederfellner G, Pastan I. Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro results. Sci Rep. 2015; 5:10832. PMID: 26111884; PMCID: PMC4482048; DOI: 10.1038/srep10832;
  8. Hollevoet K, Mason-Osann E, Müller F, Pastan I. Methylation-associated partial down-regulation of mesothelin causes resistance to anti-mesothelin immunotoxins in a pancreatic cancer cell line. PLoS One. 2015; 10(3):e0122462. PMID: 25803818; PMCID: PMC4372481; DOI: 10.1371/journal.pone.0122462;
  9. Manning ML, Mason-Osann E, Onda M, Pastan I. Bortezomib reduces pre-existing antibodies to recombinant immunotoxins in mice. J Immunol. 2015 Feb 15; 194(4):1695-701. PMID: 25560410; PMCID: PMC4323725; DOI: 10.4049/jimmunol.1402324;
  10. Hollevoet K, Mason-Osann E, Liu XF, Imhof-Jung S, Niederfellner G, Pastan I. In vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer. Mol Cancer Ther. 2014 Aug; 13(8):2040-9. PMID: 24928849; PMCID: PMC4142475; DOI: 10.1158/1535-7163.MCT-14-0089-T;

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 10 publications over 6 distinct years, with a maximum of 3 publications in 2015 and 2019


In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Alternative Lengthening of Telomeres
Cancer biology
Therapeutic development
Contact for Mentoring:
Mason-Osann's Networks
Click the "See All" links for more information and interactive visualizations
Similar People